Related by context. All words. (Click for frequent words.) 72 statistically significant 71 nonfatal MI 70 statistically nonsignificant 69 multivariate adjustment 68 P = .# 67 HbA 1c levels 67 CVD mortality 66 definite stent thrombosis 65 reach statistical significance 65 confidence interval CI 65 univariate analysis 65 MADRS score 65 % CI #.#-#.# [002] 65 HbA 1c 64 binary restenosis 64 confidence interval #.#-#.# 64 extrapyramidal symptoms 64 nondiabetic patients 64 periprocedural 64 postintervention 64 arterial thromboembolic events 63 p = NS 63 statistically significant p = 63 β blockers 63 serum urate 63 MMSE scores 63 p = #.# [003] 63 nonfatal myocardial infarction 63 reinfarction 63 % CI #.#-#.# [006] 63 tirofiban 63 oxycodone CR 63 p = .# [002] 63 univariate analyzes 63 HbA1C levels 63 Hb A1C 63 tHcy 62 UACR 62 univariate 62 systolic BP 62 posttreatment 62 nonfatal stroke 62 intima media thickness 62 achieved statistical significance 62 fasting insulin 62 colorectal adenoma 62 advanced adenoma 62 highest tertile 62 CCyR 62 p = 62 multivariable analysis 62 TEAEs 62 multivariable adjusted 62 % CI #.#-#.# [007] 62 adenoma recurrence 62 CI -#.# 62 serum triglycerides 62 p = #.# [002] 61 PSA nadir 61 creatinine ratio 61 HbA1c levels 61 lowest tertile 61 MACCE 61 Subgroup analyzes 61 eplerenone 61 LVEF 61 MetS 61 placebo p = 61 tertiles 61 placebo fluoxetine 61 #.#/#.# mmHg [001] 61 myocardial infarction MI 61 nonsignificant difference 61 biochemical recurrence 61 methotrexate monotherapy 61 serum BDNF 61 NIHSS score 61 MMSE score 61 tertile 61 LV dysfunction 61 μmol L 61 cerebrovascular events 61 serum parathyroid hormone 61 statistically significant p 61 covariate 61 multivariate Cox 61 ipsilateral stroke 61 intact parathyroid hormone 61 NYHA functional class 61 nonresponders 61 CHD mortality 61 advanced adenomas 61 symptomatic VTE 61 CI #.#-#.# [002] 61 neurodevelopmental impairment 61 statistically significant differences 61 severe exacerbations 60 logistic regression model 60 lumbar spine BMD 60 ziprasidone 60 thromboembolic 60 NIHSS 60 Primary endpoints 60 HOMA IR 60 infarct size 60 p = .# [001] 60 statistically significant reduction 60 cardiovascular mortality 60 albumin excretion rate 60 Secondary endpoints included 60 placebo 60 ATACAND 60 clinically insignificant 60 carotid IMT 60 % CI #.#-#.# [008] 60 confidence intervals CIs 60 abciximab 60 apolipoprotein B 60 multivariate analyzes 60 glycated hemoglobin HbA1c 60 NIH CPSI 60 carotid intima media 60 symptom exacerbation 60 Montgomery Åsberg Depression 60 composite endpoint 60 PASI scores 60 elevated LDH 60 hip BMD 60 hydroxyvitamin D levels 60 unfractionated heparin 59 myocardial infarctions 59 hemoglobin A1c levels 59 HDRS 59 TT genotype 59 macroalbuminuria 59 Univariate analysis 59 Brief Psychiatric 59 atheroma volume 59 DAS# [002] 59 glycated hemoglobin levels 59 % Confidence Interval 59 serum creatinine levels 59 Fasting plasma glucose 59 EDSS scores 59 pioglitazone 59 endometrial thickness 59 SGRQ 59 Montgomery Asberg Depression 59 ADAS Cog 59 β blocker 59 CDAI score 59 QTc 59 thromboembolic events 59 polyp recurrence 59 beta carotene supplementation 59 lispro 59 elevated ALT 59 insulin detemir 59 revascularizations 59 angiographic restenosis 59 VT VF 59 myocardial infarction stroke 59 postoperative complication 59 femoral neck BMD 59 recurrent venous thromboembolism 59 serum PSA 59 alanine aminotransferase 59 beta blocker therapy 59 macrovascular 59 affective psychosis 59 recurrent ischemia 59 serum estradiol 59 QTcF 59 bronchopulmonary dysplasia 59 pCR 59 repeat revascularization 59 Index CDAI 59 prespecified secondary 59 neutrophil counts 59 Stent thrombosis 59 Rating Scale MADRS 59 noncardiovascular mortality 59 p = #.# [004] 59 NNT = 59 DMARD 59 urinary albumin 59 HF hospitalization 59 attain statistical significance 58 hippocampal volume 58 UPDRS 58 mL/min/#.# m 2 58 laboratory abnormalities 58 nonobese 58 diastolic BP 58 serum uric acid 58 Crohn Disease Activity 58 highest quintile 58 lipid lowering drugs 58 perioperative complications 58 hemoglobin concentrations 58 nonsignificant trend 58 triglyceride concentration 58 autonomic dysfunction 58 liver histology 58 preoperative chemotherapy 58 Postoperative 58 CsA 58 mg BID dose 58 periprocedural MI 58 multivariable adjustment 58 severe hypoglycemia 58 contrast induced nephropathy 58 noncarriers 58 CR nPR 58 BMI z 58 left ventricular systolic 58 baseline HbA1c 58 locoregional recurrence 58 bezafibrate 58 plasma cortisol 58 aspartate aminotransferase AST 58 complete cytogenetic response 58 death reinfarction 58 carotid stenosis 58 glycosylated hemoglobin 58 noncardiac 58 tapentadol ER 58 morphometric vertebral fractures 58 haematologic 58 Kaplan Meier survival 58 WOMAC pain 58 adjunctive placebo 58 multivariate analysis 58 recurrent VTE 58 #mg/day [001] 58 hypoglycemic events 58 HbA 1C 58 glycosylated hemoglobin HbA1c 58 androgen suppression 58 nmol L 58 Erythropoietic therapies may 58 A1c levels 58 thyrotropin levels 58 XIENCE V demonstrated 58 mRS 58 Kaplan Meier analysis 58 placebo p 58 Doxil ® 58 CI #.#-#.# [001] 58 flow mediated dilation 58 IPSS 58 YMRS 58 serum homocysteine 58 euthyroid 58 fructosamine 58 severe hypoglycemic 58 chlorthalidone 58 coronary stenosis 58 microalbuminuria 58 salmeterol HFA MDI 58 β = 58 CC genotype 58 AST ALT 58 valsartan 58 SUVmax 58 prospectively defined 58 achieved ACR# 58 tiotropium 58 postoperative mortality 58 lipid lowering therapy 57 leukopenia 57 rs# [002] 57 thromboembolism 57 cilostazol 57 6MWD 57 nonvertebral fractures 57 irbesartan 57 WOMAC scores 57 coronary calcification 57 PSADT 57 DAS# scores 57 ejection fractions 57 HBeAg negative patients 57 posttransplant 57 postoperative AF 57 tolterodine ER 57 extrapyramidal side 57 candesartan 57 glomerular filtration rate 57 postop 57 symptomatic intracerebral hemorrhage 57 serum vitamin D 57 plasma homocysteine 57 noninferiority 57 dexmedetomidine 57 prespecified 57 divalproex 57 systemic embolism 57 subclinical hyperthyroidism 57 hsCRP levels 57 timepoints 57 Psoriasis Area 57 serum HBV DNA 57 % CI #.#-#.# [004] 57 chlorambucil 57 peak VO2 57 febrile neutropenia 57 virologic failure 57 ADCS CGIC 57 HbA1C 57 triglyceride concentrations 57 ischemia driven 57 cranial irradiation 57 atorvastatin #mg 57 lamotrigine 57 certolizumab 57 hypertensives 57 vertebral fracture 57 serum cortisol 57 albuminuria 57 sirolimus stent 57 gross hematuria 57 DAS# remission 57 5-FU/LV 57 apnea hypopnea index 57 mmol L 57 Bonferroni correction 57 nmol liter 57 NYHA class 57 placebo dexamethasone 57 postprocedure 57 fibrinolysis 57 EDSS score 57 urine albumin 57 elevated IOP 57 ANOVA 57 creatinine levels 57 postdischarge 57 rhinoconjunctivitis 57 pT3 57 serum urate levels 57 coronary artery calcification 57 nmol l 57 estimated GFR 57 serum concentrations 57 serologically active patients 57 NPH insulin 57 unmeasured confounders 57 subclinical hypothyroidism 57 CI = 57 Secondary endpoints 57 covariates 57 thrombotic events 57 -#.# ± [002] 57 discontinuations due 57 extracapsular extension 57 Kaplan Meier curves 57 interobserver reliability 57 airway responsiveness 57 statistical significance p 57 plasma leptin 57 fatal myocardial infarction 57 urodynamic parameters 57 IRLS score 57 % CI #.#-#.# [003] 57 fasting glucose levels 57 depressive symptom 57 Y BOCS 57 hemoglobin A1c HbA1c 57 residual confounding 57 TMP SMX 57 undetectable HBV DNA 56 NSTEMI 56 hematologic toxicity 56 hypoxemia 56 preintervention 56 rimonabant #mg 56 glycated hemoglobin 56 endoscopic remission 56 fondaparinux 56 salmeterol fluticasone propionate 56 caspofungin 56 dose statin therapy 56 ADAS cog 56 liver transaminases 56 intima media thickness IMT 56 refractory ischemia 56 subclinical atherosclerosis 56 elevated troponin 56 Unified Parkinson Disease 56 HbA1c 56 leucopenia 56 Hazard Ratio 56 FOLPI 56 secondary endpoint 56 receiving ISENTRESS 56 glomerular filtration 56 logistic regression analyzes 56 platelet reactivity 56 clinically meaningful 56 Hazard Ratio HR 56 #mmHg [001] 56 overt hypothyroidism 56 acute coronary 56 intraobserver 56 coronary revascularization 56 perioperative mortality 56 borderline statistical significance 56 treatment emergent adverse 56 stent binary restenosis 56 glimepiride 56 preoperative PSA 56 leukocyte count 56 serum CRP 56 pretest probability 56 alanine aminotransferase ALT 56 statistical significance 56 P ≤ 56 DAS# CRP 56 homocysteine concentrations 56 mEq L 56 echocardiographic parameters 56 rosuvastatin 56 sleeve lobectomy 56 serum testosterone 56 rCBF 56 diameter stenosis 56 noncardiovascular 56 normotensive 56 albumin excretion 56 alteplase 56 OGTT 56 Baseline characteristics 56 Serum creatinine 56 ropivacaine 56 idraparinux 56 serum lipid levels 56 nondiabetics 56 p ≤ 56 D dimer 56 neoadjuvant chemotherapy 56 troponin T 56 ADCS ADL 56 Kaplan Meier estimates 56 alanine transaminase 56 arterial oxygen saturation 56 CDAI 56 hematologic adverse 56 lipid lowering agents 56 μg L 56 ALND 56 serum glucose 56 μg kg 56 -#.# mg dL [001] 56 ≥ 56 pg mL 56 FDA defined valvulopathy 56 ACR# response 56 Negative Syndrome 56 XIENCE V PROMUS Stent 56 umol L 56 transaminase elevations 56 CLA supplementation 56 androgen deprivation 56 PCWP 56 exhaled NO 56 desvenlafaxine succinate 56 Operative mortality 56 colorectal neoplasia 56 cystatin C 56 methacholine challenge 56 Secondary efficacy endpoints 56 Exclusion criteria 56 Ishak fibrosis score 56 plasma lipids 56 = #.#-#.# 56 MMSE 56 mmol l 56 #OHD 56 Rating Scale BPRS 56 protein excretion 56 subscale scores 56 annualized relapse 56 urate lowering therapy 56 hematologic parameters 56 serum folate 56 comparator arm 56 treat NNT 56 hypoglycemic episodes 56 arterial thickening 56 left ventricular dysfunction 56 Depressive symptoms 56 nonfasting triglycerides 56 dyslipidaemia 56 estimated glomerular filtration 56 interquartile range 56 visceral adiposity 56 QIDS SR 56 rosuvastatin #mg 56 severe periodontitis 56 solifenacin 55 odds ratios ORs 55 fasting plasma glucose 55 ACEIs 55 URTI 55 clinically meaningful reductions 55 sirolimus eluting stent 55 scintigraphic 55 IBDQ 55 histologically confirmed 55 PaO 2 55 revascularization procedures 55 impaired fasting glucose 55 octreotide LAR 55 tipranavir r 55 paclitaxel eluting stents 55 vasopressor 55 clinicopathological 55 antihypertensive therapy 55 concomitant medications 55 conjugated equine estrogen 55 paricalcitol 55 inhospital mortality 55 anemia hemoglobin 55 FOLFIRI 55 atherogenic dyslipidemia 55 Score DAS# 55 SLNB 55 hyperhomocysteinemia 55 mg ustekinumab 55 olmesartan 55 FOLFIRI alone 55 spine BMD 55 colorectal cancer incidence 55 proteinuria 55 lipid lowering medications 55 pulmonary exacerbations 55 leukocytosis 55 dose Iluvien 55 VADT 55 thiazide diuretics 55 conditional logistic regression 55 dapagliflozin plus 55 pamidronate 55 n = 55 salmeterol fluticasone 55 HER2 expression 55 UPDRS scores 55 baseline FEV 55 logistic regression analysis 55 noncancer 55 FOLFOX4 55 oral hypoglycemic agents 55 nondepressed 55 NNRTI resistance 55 sputum eosinophils 55 adenotonsillectomy 55 bivalirudin monotherapy 55 ALT flares 55 #OHD levels 55 CTEPH 55 serum sodium levels 55 GPIIb IIIa inhibitors 55 nonobstructive 55 subthreshold depression 55 Subgroup analysis 55 tolvaptan 55 myocardial infarctions MIs 55 nmol L. 55 antioxidant supplementation 55 racemic albuterol 55 stent thromboses 55 QTc prolongation 55 colorectal adenomas 55 eptifibatide 55 abacavir lamivudine 55 noninferior 55 ertapenem 55 symptom severity 55 inotropic 55 aspirin clopidogrel 55 ximelagatran 55 events MACE 55 sociodemographic characteristics 55 ramipril 55 eszopiclone 55 perimenopausal women 55 ECG abnormalities 55 adjuvant radiotherapy 55 #Gy 55 obstructive CAD 55 lopinavir r arm 55 virologic response 55 biochemical relapse 55 endometrial hyperplasia 55 systemic corticosteroid 55 benazepril 55 HAM D# 55 tibolone 55 BENICAR HCT 55 mcg ml 55 tamsulosin 55 prolactin elevation 55 Key secondary endpoints 55 serum potassium 55 timepoint 55 elevated bilirubin 55 % CI #.#-#.# [001] 55 median survivals 55 transferrin saturation 55 pmol L 55 LV ejection fraction 55 Taxus Stent 55 symptomatic intracranial hemorrhage 55 symptomatic intracranial 55 oral prednisolone 55 carotid plaque 55 fasting plasma insulin 55 intracerebral hemorrhage 55 bivariate 55 myocardial ischemia 55 histologic 55 fetal malformations 55 MDRD 55 cardiovascular morbidity 55 depressive symptomatology 55 comorbidity 55 insulin glargine 55 hepatic enzymes 55 subgroup analyzes 55 genotypic resistance 55 enalapril 55 #mg BID [001] 55 postoperative chemotherapy 55 systolic dysfunction 55 specific antigen PSA 55 diastolic pressures 55 PANSS total 55 squamous histology 55 hormone receptor negative 55 pegaptanib 55 carotid bruit 55 nonrandomized 55 renal insufficiency 55 dobutamine 55 OADs 55 systolic blood pressures 55 #mm Hg 55 angiotensin converting enzyme inhibitors 55 somatic symptom 55 CYP#D# inhibitor 55 g dL 55 mg dL 55 thrombolytic therapy 55 aminotransferases 55 mammographic density 55 Insulin sensitivity 55 mIU L 55 montelukast 55 nonfasting triglyceride levels 55 distant metastasis 55 ventricular remodeling 55 GP IIb IIIa inhibitors 55 Alzheimer Disease Assessment 55 intracerebral haemorrhage 55 LEXIVA r 55 hematological adverse 55 polytherapy 55 multivariable Cox 55 serum phosphate 55 mitoxantrone 55 neurocognitive function 55 plasma glucose 55 creatine kinase 55 sirolimus eluting stents 55 QTc intervals 55 locoregional 55 dietary folate intake 55 PANSS scores 55 rheumatoid factor 55 ventricular mass 55 TDF FTC 55 recurrent ischemic 55 subscore 55 ezetimibe simvastatin 55 seropositive patients 55 asthma exacerbation 54 -#.# log# 54 nasal polyposis 54 interobserver 54 bronchial hyperresponsiveness 54 dyssynchrony 54 nonadherence 54 hemorrhagic complications 54 pairwise comparisons 54 REYATAZ r arm 54 inflammatory biomarkers 54 lignan intake 54 plus methotrexate 54 fluoxetine 54 PANSS 54 olanzapine 54 serum ALT 54 recurrent DVT 54 nadroparin 54 conventional antipsychotics 54 mg kg dose 54 aspartate aminotransferase 54 discontinuations 54 dalteparin 54 Complication rates 54 #.#mmHg 54 lipid parameters 54 ALT elevation 54 Events MACE 54 mcg QD 54 myocardial infarction 54 urinary calcium 54 elevated homocysteine 54 macrovascular events 54 Flu Cy 54 left ventricular hypertrophy 54 oxcarbazepine 54 comorbid 54 ABC/3TC 54 elevated CRP 54 mTSS 54 serum sodium 54 hemoglobin A1C 54 sUA 54 ALSFRS R 54 HRQoL 54 GIK infusion 54 confounding variables 54 SNP rs# [002] 54 micafungin 54 abdominal adiposity 54 lipid profiles 54 prostate cancer CaP 54 serum magnesium 54 serum cotinine levels 54 adalimumab 54 transaminases 54 hepatic enzyme 54 mg BID 54 urinary oxalate 54 graft occlusion 54 rebleeding 54 Secondary endpoints include 54 Postoperative complications 54 CANCIDAS 54 secondary efficacy endpoints 54 nodal metastases 54 doxorubicin docetaxel 54 mg dose 54 elevated creatinine 54 CNS systemic embolism 54 metabolic parameters 54 HAQ DI 54 serum IGF 54 myocardial reperfusion 54 depressive symptoms 54 Pioglitazone 54 selenium supplementation 54 HBeAg seroconversion 54 serum phosphate levels 54 secondary efficacy endpoint 54 neutropaenia 54 Apgar scores 54 transaminase levels 54 dose clopidogrel 54 sustained ventricular tachycardia 54 non affective psychosis 54 diastolic blood pressures 54 psychiatric comorbidity 54 clinically meaningful improvements 54 psychosocial variables 54 comorbid conditions 54 HSCT 54 PSQI 54 diuretic chlorthalidone 54 ischemic lesions 54 IOP lowering 54 sociodemographic factors 54 inverse association 54 #.#mmol L [002] 54 fasting plasma 54 terazosin 54 fosamprenavir 54 Platelet counts 54 amisulpride 54 syncopal 54 cryptogenic 54 virological response 54 plasma homocysteine levels 54 familial AF 54 achieve statistical significance 54 antibody titer 54 pulmonary dysfunction 54 serum triglyceride 54 rs# [003] 54 heterozygotes 54 probable stent thrombosis 54 T2 lesion volume 54 regression coefficient 54 premorbid 54 triacylglycerol concentrations 54 angiotensin II receptor blockers 54 subtrochanteric 54 thrombocytopenic 54 etanercept 54 mycophenolate mofetil 54 primary aldosteronism 54 parous women 54 ARB telmisartan 54 fibrinolytic therapy 54 NMIBC 54 rs# [004] 54 glycosylated hemoglobin levels 54 postoperative complications 54 Ramipril 54 fragility fracture 54 endarterectomy 54 statistically significant predictor 54 potential confounders 54 cardiovascular hospitalizations 54 hydroxyvitamin D concentrations 54 surgically induced 54 Scale EDSS score 54 asymptomatic carotid stenosis 54 STN stimulation 54 prolonged QT interval 54 creatinine clearance 54 serum bilirubin 54 mmHg diastolic 54 ß blockers 54 ARCOXIA 54 Triglyceride levels 54 retinal thickness 54 metformin monotherapy 54 cabazitaxel 54 dose atorvastatin 54 clopidogrel 54 nicardipine 54 GnRH agonist 54 Major Adverse Cardiac 54 fasting plasma glucose FPG 54 clomipramine 54 glycoprotein IIb IIIa inhibitors 54 parkinsonism 54 hsCRP 54 COPD exacerbation 54 events TEAEs 54 HAM D# scores 54 thyroglobulin 54 plasma glucose levels 54 salivary cortisol 54 flutamide 54 SSRI SNRI 54 subscores 54 plus medroxyprogesterone acetate 54 tumor recurrence 54 dietary calcium intake 54 atherothrombotic 54 antihypertensive medication 54 aripiprazole 54 corticosteroid dose 54 cerebral infarction 54 urinary excretion 54 â ‰ ¥ 54 mcg BID 54 HAM D 54 oophorectomy 54 levosimendan 54 white matter hyperintensities 54 LVSD 54 histologic subtype 54 serum cholesterol 54 baseline LDH 54 T2 lesions 54 venlafaxine XR 54 retrospective cohort 54 triamcinolone 54 upper gastrointestinal bleeding 54 pg ml 54 resuscitated cardiac arrest 54 Pred Forte 54 macrovascular disease 54 confirmed CCyR 54 incomplete revascularization 54 ocular adverse 54 pneumonectomy 54 multivariate logistic regression 54 elevated serum creatinine 54 statistically significant correlation 54 adiponectin concentrations 54 unfractionated heparin UFH 54 CIN3 54 renal dysfunction 54 arterial occlusion 54 FluCAM 54 avosentan 54 clodronate 54 nasopharyngitis headache 54 pentoxifylline 54 paraprotein 54 amoxicillin clavulanate 54 ventricular dysfunction 54 seminal vesicle invasion 54 CHADS 54 IPAH 54 RBP4 levels 54 sinus rhythm 53 femoral neck fracture 53 cardiac dysfunction 53 exacerbations 53 spirometric 53 poststroke 53 aldosterone antagonist 53 tic severity 53 bivariate analyzes 53 LS BMD 53 systolic hypertension 53 ± SD 53 plasma selenium 53 relapsers 53 primary percutaneous coronary 53 μg dL 53 SHBG levels 53 distensibility 53 recurrent myocardial infarction 53 PUFA intake 53 arterial thromboembolism 53 bosentan 53 Thal Dex 53 tHcy concentrations 53 patients undergoing CABG 53 bivariate analysis 53 paresthesias 53 UPDRS motor 53 prednisone prednisolone 53 endotoxin exposure 53 metabolite concentrations 53 lopinavir r 53 non inferiority 53 T2DM 53 Multivariate analysis 53 serum selenium 53 enoxaparin 53 curative resection 53 divalproex sodium 53 #.#ng/ml 53 lymphocytosis 53 clinically meaningful differences 53 adjuvant chemotherapy 53 plasma HCV RNA 53 clinically meaningful improvement 53 RNFL thickness 53 atherosclerotic progression 53 isolated systolic hypertension 53 hippocampal atrophy 53 bilateral oophorectomy 53 artery calcification 53 poor metabolizers 53 kcal d 53 TAXUS p value 53 mg TID 53 cerebral microbleeds 53 Timed Walk 53 invasive ductal 53 Neuropsychiatric Inventory 53 sperm morphology 53 retrograde ejaculation 53 intensive statin therapy 53 inversely associated 53 nephrotoxicity 53 coinfected patients 53 underwent CABG 53 sustained virologic response 53 -#.# mg dL [002] 53 HBeAg 53 4mg/kg 53 microvascular disease 53 surrogate markers 53 FEV1 53 nonfasting 53 hypercoagulable 53 apnea hypopnea 53 acute cholecystitis 53 metoprolol tartrate 53 #.#mmol L [001] 53 #mg/day [002] 53 ANCOVA 53 tapentadol IR 53 KIF6 carriers 53 serum calcium 53 FOLFOX 53 aOR 53 tipranavir ritonavir